Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken

Acacia Pharma Terug naar discussie overzicht

Acacia pharma 2022 op naar de top!

1.195 Posts
Pagina: «« 1 ... 33 34 35 36 37 ... 60 »» | Laatste | Omlaag ↓
  1. forum rang 7 lucas D 25 maart 2022 16:21

    • lucas D

      Lid sinds: 27 jun 2007

      Laatste bezoek: 08 feb 2025

    • Aanbevelingen

      Ontvangen: 10614

      Gegeven: 8170

    •    Aantal posts: 30.877

    quote:

    Reacher schreef op 25 maart 2022 14:48:

    [...]

    Hoeveel van jouw verwachtingen zijn er uitgekomen? Je bent samen met Sirlander een mooi struisvogelkoppel
    Vanaf september 2021 heb ik al aangegeven dat de huidige koersen de laagste ooit 1,050 - 1,600 zijn in de geschiedenis van Acacia.
    Daar is niets aan veranderd.
    Ik schreef over kansen, kansen kansen en dat doe ik nog altijd. Niemand hoeft daar een boodschap aan te hebben, maar kom niet aan met dat Acacia Pharma geen toekomst heeft op het moment dat deze er meer dan ooit het geval was is.

    Wat jij vind is helemaal niet interessant en relevant.
  2. Em Ha 25 maart 2022 17:41

    • Em Ha

      Lid sinds: 06 jul 2020

      Laatste bezoek: 01 feb 2025

    • Aanbevelingen

      Ontvangen: 158

      Gegeven: 95

    •    Aantal posts: 346

    Zoals al 100x aangegeven wellicht interessant voor de lange termijn, dat is afwachten. Op de korte termijn verwacht ik niks van, we zien het wel. Op de plank ermee!
    Hopelijk checkt de operator eens goed de berichten zodat jij een van krijgt. Man wat een gezanik zo voor het weekend.
  8. forum rang 10 DeZwarteRidder 28 maart 2022 08:17

    • DeZwarteRidder

      Lid sinds: 29 jun 2012

      Laatste bezoek: 08 feb 2025

    • Aanbevelingen

      Ontvangen: 24062

      Gegeven: 10521

    •    Aantal posts: 101.955

    Offer by Eagle Pharmaceuticals, Inc.
    Acacia Pharma Group plc
    Mon, March 28, 2022, 8:00 AM·8 min read

    PROPOSED TRANSACTION WITH EAGLE PHARMACEUTICALS, INC.

    THIS ANNOUNCEMENT CONTAINS REGULATED INFORMATION AND INSIDE INFORMATION

    Not for release, publication or distribution, in whole or in part, directly or indirectly in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction

    For immediate release

    28 March 2022, 08:00 a.m. (Brussels time)

    RECOMMENDED SCHEME OF ARRANGEMENT

    of

    ACACIA PHARMA GROUP PLC

    by

    EAGLE PHARMACEUTICALS, INC.

    to be effected by means of a Scheme of Arrangement
    under Part 26 of the Companies Act 2006

    Summary

    This summary should be read in conjunction with, and is subject to, the full text of the following announcement (including its Appendices).

    Key highlights

    Acacia Pharma Group PLC (“Acacia”) met its formulary goals for both Barhemsys® and Byfavo® in FY2021 and continues to be encouraged that feedback for both products is indicative of significant future commercial potential.

    However, Acacia’s standalone financial condition has been negatively impacted by physical access limitations caused by the global COVID-19 pandemic, and a significant latency of demand due to postponement of surgical procedures. Accordingly, Acacia expects it would require a minimum of approximately US$115m of additional cash to fund operations to break-even (based on projections assuming break-even by early FY2025).

    As a result, the Acacia Board appointed Greenhill to undertake a comprehensive review of strategic alternatives available to maximise value for Acacia Shareholders. The review included consideration of options to raise additional capital, but found that the terms on which such capital was likely to be available would have led to significant dilution and potential destruction of value for Acacia Shareholders.

    Following this comprehensive exploration and assessment of all strategic alternatives, the board of directors of Acacia and the board of directors of Eagle Pharmaceuticals, Inc. (“Eagle”) hereby announce that they have reached agreement on the terms of a transfer of the entire issued and to be issued share capital of Acacia to Eagle by way of a scheme of arrangement under Part 26 of the Companies Act 2006 (the “Proposed Transaction”).

    Under the terms of the Proposed Transaction, each Scheme Shareholder will receive as consideration (the “Consideration”):

    for each Scheme Share, €0.68 in cash and 0.0049 New Eagle Shares

    The Proposed Transaction values Acacia’s existing issued and to be issued share capital at approximately €94.7 million on a fully diluted basis.

    The cash portion of the Consideration represents approximately 75 per cent. of the total Consideration, and the New Eagle Shares that Acacia Shareholders would receive represent approximately 25 per cent. of the total Consideration, which represents approximately 3.8 per cent. of the enlarged Eagle share capital in issue immediately following completion of the Scheme. The total Consideration equates to €0.90 for each Scheme Share.

    The Consideration provides Acacia Shareholders with both up-front cash and, through the New Eagle Shares to be acquired by Acacia Shareholders, equity participation in the value creation potential for the enlarged business through de-risked funding requirements, enlarged group synergies, and being part of a well-funded entity with shares trading on a liquid exchange.

    Having considered all of the available alternatives as part of its strategic review, the Acacia Board believes that the Proposed Transaction represents the best option for Acacia Shareholders to maximise the value of their shares, and therefore unanimously recommends the Proposed Transaction.

    Furthermore, the Acacia Board considers that there is a significant risk that if the Scheme is not approved by the necessary number of Acacia Shareholders, this could lead to a very material reduction in the value attributable to Acacia Shares and/or an insolvency procedure relating to the Acacia Group, which could in turn result in negligible (if any) value being attributable to Acacia Shares.

    In making its recommendation, the board of Acacia has considered the financial position of Acacia given the significant operational challenges as a result of the limited physical access to institutions resulting from the global COVID-19 pandemic, as well as the significant latency of demand due to the postponement of non-essential surgical procedures, as a result of which the Acacia Group has experienced a significant reduction in its available liquidity as the net revenue in 2021 and so far in 2022 continues to lag behind expectations.

    Recommendation, irrevocable undertakings and shareholder support for the Proposed Transaction

    The Acacia Directors consider the Proposed Transaction to be the best available option for Acacia Shareholders. In making this assessment, the Acacia Directors have received financial advice from Greenhill who, in providing its financial advice, has taken into account the commercial assessments of the Acacia Directors. Accordingly, the Acacia Directors intend unanimously to recommend that Acacia Shareholders vote in favour of the Scheme at the Court Meeting and the Resolutions to be proposed at the General Meeting, as the Acacia Directors have irrevocably undertaken to do in respect of the 217,543 Acacia Shares which they hold and which they control (or can procure the control of) the voting rights, representing approximately 0.22 per cent. of the issued share capital of Acacia on 25 March 2022, being the last business day before this announcement.

  9. forum rang 10 DeZwarteRidder 28 maart 2022 08:17

    • DeZwarteRidder

      Lid sinds: 29 jun 2012

      Laatste bezoek: 08 feb 2025

    • Aanbevelingen

      Ontvangen: 24062

      Gegeven: 10521

    •    Aantal posts: 101.955

    2)

    In addition to the irrevocable undertakings referred to above, Eagle has also received irrevocable undertakings from the three largest shareholders of Acacia to vote in favour of the Scheme at the Court Meeting and the Resolutions to be proposed at the General Meeting in respect of the 49,012,875 Acacia Shares which they hold and which they control (or can procure the control of) the voting rights, representing approximately 48.56 per cent. of the issued share capital of Acacia on 25 March 2022, being the last business day before this announcement.

    Therefore, Eagle has received irrevocable undertakings representing, in aggregate, 49,230,418 Acacia Shares representing approximately 48.78 per cent. of the issued share capital of Acacia.

    Further details of these irrevocable undertakings, including the circumstances in which they cease to be binding, are set out in Appendix 3 to this announcement.

    Information on Eagle

    Eagle is a fully integrated pharmaceutical company with research and development, clinical, manufacturing and commercial expertise. Eagle is committed to developing innovative medicines that result in meaningful improvements in patients’ lives. Eagle’s commercialised products include vasopressin injection, PEMFEXY™, RYANODEX®, BENDEKA®, BELRAPZO®, TREAKISYM (Japan), and its oncology and CNS/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. Additional information is available on Eagle’s website at www.eagleus.com.

    Eagle is listed with shares of its common stock publicly traded on Nasdaq under the trading symbol “EGRX” and has a market capitalisation of approximately US$615 million as at 25 March 2022, being the last business day before this announcement.

    Comments on the Proposed Transaction

    Commenting on the Proposed Transaction, Scott Byrd, Chairman of Acacia, said:

    “I am proud of the progress that Acacia has achieved in bringing Barhemsys® through clinical trials to the market and in the progress it has subsequently made in launching both this product and Byfavo® in the US. Both products are designed to address clear and important hospital needs and to date have received positive feedback from customers and strong formulary acceptance, positioning them well for future success. However, the global COVID-19 pandemic has resulted in significant and sustained challenges that have significantly disrupted hospital operations, limited access, and dramatically increased the time and investment required for product launches.

    The Acacia Board believes this Proposed Transaction represents an opportunity for Acacia shareholders to realise value for their investment in cash and, through Eagle, retain an interest in the future value that may be generated from Barhemsys® and Byfavo® being part of a larger portfolio of hospital products, in the hands of a well-capitalised company. We are therefore unanimously recommending this Proposed Transaction to our shareholders.”

    Commenting on the Proposed Transaction, Scott Tarriff, President and Chief Executive Officer of Eagle, said:

    “We are delighted to announce that we have agreed to terms for the proposed acquisition of Acacia. This will be a very important acquisition for us, both financially and strategically. In recent years, the pharmaceutical industry has witnessed slower uptake of new products and longer ramp periods. In the face of further challenges brought about by the COVID-19 pandemic, many smaller underfunded companies experienced significant hurdles launching products. We therefore believe that Eagle is well suited to drive uptake of these two new products, building from Acacia’s established foundation since its launch, through our experienced and specialised hospital-based sales organisation with minimal additional infrastructure.”
  15. Rode Duivel 28 maart 2022 08:57

    • Rode Duivel

      Lid sinds: 10 jul 2019

      Laatste bezoek: 08 feb 2025

    • Aanbevelingen

      Ontvangen: 359

      Gegeven: 211

    •    Aantal posts: 1.553

    quote:

    Sirlander schreef op 28 maart 2022 08:30:

    Ik veronderstel dat het aandeel wordt geschorst?

    Neen, want ze moeten aandeelhouders de kans geven om te kiezen tussen nu verkopen of het aanbod aanvaarden en cash + Eagle aandelen verkrijgen. Het aanbod moet volgens mij ook nog officieel goedgekeurd worden op een bijzondere aandeelhoudersvergadering.
  16. forum rang 10 voda 28 maart 2022 08:59

    • voda

      Lid sinds: 02 dec 2005

      Laatste bezoek: 08 feb 2025

    • Aanbevelingen

      Ontvangen: 92667

      Gegeven: 22751

    •    Aantal posts: 382.883

    Bod op Acacia Pharma | Handel opgeschort

    Eagle Pharmaceuticals doet een bod van 94,7 miljoen euro op Acacia Pharma ACPH 0,00% . Elke aandeelhouder van Acacia krijgt per aandeel Acacia 0,68 euro cash en 0,0049 aandelen Eagle.

    Acacia sloot vrijdag af op 1,28 euro, goed voor een beurswaarde van 129 miljoen euro. Het bod impliceert dan ook een korting van 29,7 procent. De raad van bestuur van Acacia staat unaniem achter het bod.

    De FSMA heeft de handel in Acacia opgeschort.

    www.tijd.be/markten-live/live-blog/bo...
  17. Sirlander 28 maart 2022 09:02

    • Sirlander

      Lid sinds: 09 jan 2018

      Laatste bezoek: 08 mrt 2024

    • Aanbevelingen

      Ontvangen: 721

      Gegeven: 182

    •    Aantal posts: 4.439

    quote:

    Rode Duivel schreef op 28 maart 2022 08:57:

    [...]
    Neen, want ze moeten aandeelhouders de kans geven om te kiezen tussen nu verkopen of het aanbod aanvaarden en cash + Eagle aandelen verkrijgen. Het aanbod moet volgens mij ook nog officieel goedgekeurd worden op een bijzondere aandeelhoudersvergadering.
    FSMA heeft het aandeel geschorst.

  18. Rode Duivel 28 maart 2022 09:07

    • Rode Duivel

      Lid sinds: 10 jul 2019

      Laatste bezoek: 08 feb 2025

    • Aanbevelingen

      Ontvangen: 359

      Gegeven: 211

    •    Aantal posts: 1.553

    quote:

    Sirlander schreef op 28 maart 2022 09:02:

    [...]
    FSMA heeft het aandeel geschorst.

    Ik veronderstel dat er toch nog kan gehandeld worden vóór de transactie plaats vindt. In principe zou dat toch moeten.
  19. forum rang 5 limomilo 28 maart 2022 09:08

    • limomilo

      Lid sinds: 13 feb 2013

      Laatste bezoek: 08 feb 2025

    • Aanbevelingen

      Ontvangen: 671

      Gegeven: 558

    •    Aantal posts: 4.035

    Beleggen in Belgische Pharmafondsen is een lucratieve bezigheid. Eerst Galapagos, daarna Bone, gevolgd door Celyad en wat later Mithra. De een na de ander met negatief nieuws met dito gevolgen voor de koers.
    Nu dus ook Acacia.
  20. Sirlander 28 maart 2022 09:10

    • Sirlander

      Lid sinds: 09 jan 2018

      Laatste bezoek: 08 mrt 2024

    • Aanbevelingen

      Ontvangen: 721

      Gegeven: 182

    •    Aantal posts: 4.439

    quote:

    Rode Duivel schreef op 28 maart 2022 09:07:

    [...]
    Ik veronderstel dat er toch nog kan gehandeld worden vóór de transactie plaats vindt. In principe zou dat toch moeten.

    Ik denk dat je gewoon verplicht bent om op het bod in te gaan.
    Indien geen akkoord, gaat koers terug open met alle gevolgen vandien.
    Dus volgens mij moeten we wachten op de beslissing.
1.195 Posts
Pagina: «« 1 ... 33 34 35 36 37 ... 60 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.001
AB InBev 2 5.483
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.206
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 264
Accsys Technologies 23 10.528
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 188
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.651
Aedifica 3 901
Aegon 3.258 322.670
AFC Ajax 538 7.086
Affimed NV 2 6.288
ageas 5.844 109.885
Agfa-Gevaert 14 2.048
Ahold 3.538 74.294
Air France - KLM 1.025 35.000
AIRBUS 1 11
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.036
Alfen 16 24.334
Allfunds Group 4 1.468
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 405
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.813
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.835 242.758
AMG 971 133.102
AMS 3 73
Amsterdam Commodities 305 6.686
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 485
Antonov 22.632 153.605
Aperam 92 14.936
Apollo Alternative Assets 1 17
Apple 5 380
Arcadis 252 8.731
Arcelor Mittal 2.033 320.583
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.288
Aroundtown SA 1 219
Arrowhead Research 5 9.716
Ascencio 1 26
ASIT biotech 2 697
ASMI 4.108 39.082
ASML 1.766 106.069
ASR Nederland 21 4.451
ATAI Life Sciences 1 7
Atenor Group 1 470
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.610
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.390

Macro & Bedrijfsagenda

  1. 10 februari

    1. Industriële productie december (NL)
    2. UniCredit Q4-cijfers (Ita)
    3. NX Filtration Q4-cijfers

  2. 11 februari

    1. Kering Q4-cijfers (Fra)
    2. Wereldhave Q4-cijfers
    3. Barco Q4-cijfers
    4. Wereldhave Belgium Q4-cijfers
    5. BP Q4-cijfers (VK)
    6. Ondernemersvertrouwen mkb januari (VS)
    7. Coca-Cola Q4-cijfers (VS)
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda